ASC-618 is under clinical development by ASC Therapeutics and currently in Phase II for Hemophilia A (Factor VIII Deficiency). According to GlobalData, Phase II drugs for Hemophilia A (Factor VIII Deficiency) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ASC-618’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASC-618 is under development for hemophilia A. The drug candidate is developed based on CRISPR/Cas9 genome editing technology, TARGATT and coagulation factor VIII expression technologies. It is administered through intravenous route. The drug candidate acts by targeting coagulation factor VIII. The gene is delivered using adeno-associated virus (AAV) vector.
ASC Therapeutics overview
ASC Therapeutics is a biotechnology company which is engaged in research and development of cure for intractable and rare diseases using gene and cell therapy. It is headquartered in Milpitas, California, the US.
For a complete picture of ASC-618’s drug-specific PTSR and LoA scores, buy the report here.